The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the tyrosine kinase inhibitor Inlyta (axitinib) in the first-line treatment of advanced renal cell carcinoma (RCC).
The ruling was made on the back of Phase 3 data confirming that the combination of Keytruda and Inlyta reduced the risk of death by 47% in RCC patients compared to Pfizer’s Sutent (sunitinib), while also presenting benefit in both progression-free survival and objective response rate.
